Skip to main content
SpringerLink
Log in

Human central nervous system and plasma pharmacology of mitoxantrone

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Mitoxantrone 5–6 mg/m2 was administered IV to 10 consenting patients prior to surgical resection of an intracerebral tumor. Plasma pharmacokinetic parameters were calculated and concentration of mitoxantrone in intracerebral tumors was determined. Concentrations of mitoxantrone were also determined in autopsy tissues of one of the patients who expired 192 days after receiving the drug. The plasma pharmacokinetics were best described by a 3 compartment model, with a t1/2γ of 4.74±5.53 h. Mitoxantrone concentrations in the intracerebral tumors were potentially cytotoxic and ranged from 4 to 322 ng/g. In all but one case, mitoxantrone concentration was higher in tumor than in concurrent plasma samples. There was no obvious relation between tumor mitoxantrone concentration and peak plasma mitoxantrone concentration or time from mitoxantrone administration to tumor removal. Low grade gliomas and viable tumors tended to have lower mitoxantrone concentrations than did other tumor types and necrotic tumors. In the patient undergoing autopsy, highest mitoxantrone concentrations were found in liver, thyroid and heart.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. White RJ, Durr FE: Development of mitoxantrone. Invest New Drugs 3:85–93, 1985

    Google Scholar 

  2. Prentice HG, Robbins G, Ma DDF, Ho AD: Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. Cancer Treat Rep 10 (Suppl B):57–65, 1983

    Google Scholar 

  3. Gams RA, Kelley JW, Colomb HM, Steinberg J, Dukart G: Mitoxantrone in malignant lymphomas. Cancer Treat Rev 10 (Suppl B):69–72, 1983

    Google Scholar 

  4. Neidhart J, Goehnour D, Roach RW, Steinberg J, Young D: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial. Cancer Treat Rev 10 (Suppl B):41–46, 1983

    Google Scholar 

  5. Smith I: Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10:103–115, 1983

    Google Scholar 

  6. Alberts DS, Peng YM, Bowden T, Dalton WS, Mackel C: Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3:101–107, 1985

    Google Scholar 

  7. Alberts DS, Peng Y-M, Leigh S, Davis TP, Woodward DL: Disposition of mitoxantrone in cancer patients. Cancer Res 45:1879–1884, 1985

    Google Scholar 

  8. Ehninger G, Proksch B, Heinzel G, Schiller E, Weible K-H, Woodward DL: The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 3:109–116, 1985

    Google Scholar 

  9. Savaraj N, Lu K, Valdivieso M, Loo TL: Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 8:113–117, 1982

    Google Scholar 

  10. Roboz J, Paciucci P, Silides D, Greaves J, Holland J: Detection and quantitation of mitoxantrone in human organs. A case report. Cancer Chemother Pharmacol 13:67–68, 1984

    Google Scholar 

  11. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Research 42:2474–2479, 1982

    Google Scholar 

  12. Stewart DJ, Richard M, Hugenholtz H, Dennery J, Belanger R, Gerin-Lajoie J, Montpetit V, Nundy D, Prior J, Hopkins H: Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neuro-Oncology 2:133–139, 1984

    Google Scholar 

  13. Stewart DJ, Lu K, Benjamin RS, Leavens M, Luna M, Yap HY, Loo TL: Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neuro-Oncology 1:139–144, 1983

    Google Scholar 

  14. Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KD, Burgess MA, Loo TL: Penetration of 3-deazauridine into human brain, intracerebral tumor and cerebrospinal fluid. Cancer Research 39:4119–4122, 1977

    Google Scholar 

  15. Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL: Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Research 40:3163–3166, 1980

    Google Scholar 

  16. Rosenblum M, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL: Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans. Cancer Research 41:459–462, 1981

    Google Scholar 

  17. Savaraj N, Lu K, Feun LG, Leavens ME, Stewart D, Burgess MA, Benjamin RS, Loo TL: Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino)1,4-benzoquinone (AZQ, NSC-182986). J Neuro-Oncology 1:15–19, 1983

    Google Scholar 

  18. Zhengang G, Savaraj N, Feun LG, Lu K, Stewart DJ, Luna M, Benjamin RS, Loo TL: Tumor penetration of AMSA in man. Cancer Invest 1:475–478, 1983

    Google Scholar 

  19. Stewart DJ, Leavens M, Lu K, Wang YM, Benjamin RS, Ho DH, Yap HY, Loo TL: Central nervous system pharmacology of Baker's antifolate (NSC 139105) in man. J Neuro-Oncology 2:187–193, 1984

    Google Scholar 

  20. Stewart DJ, Richard MT, Hugenholtz H, Dennery J, Nundy D, Prior J, Montpetit V, Hopkins HS: Penetration of teniposide (VM-26) into human intracerebral tumors: preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin-B or oral glycerol. J Neuro-Oncology 2:315–324, 1984

    Google Scholar 

  21. Stewart DJ, Benvenuto J, Leavens M, Smith R, Cabanillas F, Benjamin RS, Loo TL: Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J Neuro-Oncology 1:357–364, 1983

    Google Scholar 

  22. Green RM, Hugenholtz H, Richard M, Dennery J, Hopkins H, Thibault M, Stewart DJ: Human central nervous system pharmacology of tiazofurin. Proceedings of the Second International Symposium on Biology of Brain Tumor. J Neuro-Oncology 2:288, 1984

    Google Scholar 

  23. Groothuis D, Fischer J, Vick N, Bigner D: Comparative permeability of different glioma models to horseradish peroxidase. Cancer Treat Rep 65 (Suppl 2):13–18, 1981

    Google Scholar 

  24. Stewart DJ, Hugenholtz H, Russell N, Richard MT, Benoit B, Maroun JA, Grahovac Z, Girard A, Nabwangu JF: Phase II Study of Novantrone (Mitoxantrone Hydrochloride) in Adults with Grade III–IV Astrocytomas. In: Walker MD, Thomas DGT (eds) Biology of Brain Tumor, Martinus Nijhoff Publishers, Boston, pp 411–413, 1986

    Google Scholar 

  25. Ostroy F, Gams RA: An HPLC method for the quantitative determination of 1,4-dihydroxy-5,8 bis [2-[(2-hydroxyethyl)-amino]ethyl]amino]9, 10-anthracenedione (DHAQ, Lederle Labs CL232 315, NCS 301739) in serum. J Liq Chromatog 3:637–644, 1980

    Google Scholar 

  26. Hulhoven R, Desager JP: HPLC determination of mitoxantrone in biological fluids: A sensitive and accurate method. J High Resolut Chromatog and Chromatog Commun 6:512–513, 1983

    Google Scholar 

  27. Sedman AJ, Wagner JG: CSTRIP, a Fortran IV Computer Program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65:1006–1010, 1976

    Google Scholar 

  28. Loo JCK, Riegelman S: Assessment of pharmacokinetic constants from post infusion blood curves obtained after IV infusion. J Pharm Sci 59:53–55, 1970

    Google Scholar 

  29. Von Hoff DD, Coltman Jr CA, Forseth B: Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41:1853–1855, 1981

    Google Scholar 

  30. Cowan JD, Von Hoff DD, Clark GM: Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system. Invest New Drugs 1:139–144, 1983

    Google Scholar 

  31. Traganos F, Evenson DP, Staiano-Coico L, Darzynkiewicz Z, Melamed MR: Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells. Cancer Res 40:671–681, 1980

    Google Scholar 

  32. Levin VA: A pharmacological basis for brain tumor chemotherapy. Sem Oncol 2:57–61, 1975

    Google Scholar 

  33. Broder LE, Rall DP: Chemotherapy of brain tumors. Prog Exp Tumor Res 17:373–399, 1972

    Google Scholar 

  34. Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, Maroun JA: Human autopsy tissue concentrations of mitoxantrone. Can Treat Rep 70:1255–1261, 1986

    Google Scholar 

  35. Bischoff K: Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy. Cancer Chemother Rep 59:777–793, 1975

    Google Scholar 

  36. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K: Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3:123–132, 1985

    Google Scholar 

  37. Crossley R: Clinical safety and tolerance of mitoxantrone (novantrone). Cancer Treat Rev 10 (Suppl B):29–36, 1983

    Google Scholar 

  38. Stewart DJ, Hugenholtz H, Green R, Richard M, Benoit B, Russell N, Maroun J, Thibault M: Mitoxantrone hydrochloride: Uptake into human brain tumors and phase II study in gliomas. J Neuro-Oncology 4:114, 1986

    Google Scholar 

  39. Stewart DJ, Green R, Montpetit V, Hugenholtz H, Richard M, Mikhael N, Maroun J: Human tissue (tis) concentrations (conc) of mitoxantrone (m). Proc Amer Assoc Can Res 27:167, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Ottawa, Canada

    R. M. Green, D. J. Stewart, H. Hugenholtz, M. T. Richard, M. Thibault & V. Montpetit

  2. University of Ottawa Faculty of Health Sciences, Ottawa, Canada

    R. M. Green, D. J. Stewart, H. Hugenholtz, M. T. Richard, M. Thibault & V. Montpetit

Authors
  1. R. M. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. J. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Hugenholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. T. Richard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Thibault
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Montpetit
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, R.M., Stewart, D.J., Hugenholtz, H. et al. Human central nervous system and plasma pharmacology of mitoxantrone. J Neuro-Oncol 6, 75–83 (1988). https://doi.org/10.1007/BF00163544

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00163544

Key words

Search

Navigation